Sign inJoin waitlistJoin the waitlist

Albert Kheradpour

Physician · Loma Linda Univ Sch of Med

Credentials: · · · ·

History

Loma Linda Univ Sch of Med
Present

Memorial Sloan Kettering Cancer Center
1992–1993
Firoozgar Hospital
1989–1992
Shahid Beheshti Hospital
1986–1989
Pediatrics
Overlook Medical Center
1983–1986
Memorial Sloan Kettering Cancer Center
1980–1983
Faculty of Medicine, Tehran University of Medical Sciences
1976–1980

Research

Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53…
Blood · 1995 · 116 citations
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma
Journal of Clinical Oncology · 2024 · 95 citations
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry…
Biology of Blood and Marrow Transplantation · 2018 · 29 citations

Craig Zuppan
7 papers
JB
Joseph Bertino
4 papers
ER
Edward Rowsell
3 papers
Jun Wang
3 papers
EB
Ellin Berman
2 papers
LW
Lawrence Weiss
2 papers
PM
Paul Meyers
2 papers
Soheil Meshinchi
2 papers
TT
Tanya Trippett
2 papers
Aleksandra Petrovic
1 paper
AC
Alexandra Cheerva
1 paper
Alfred Gillio
1 paper

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031